BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld Asia
Home
» Bavarian's Smallpox Vaccine Pact Worth Up To $1.6 Billion
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Bavarian's Smallpox Vaccine Pact Worth Up To $1.6 Billion
June 6, 2007
By
Cormac Sheridan
No Comments
Bavarian Nordic A/S could earn a total of $1.6 billion from its contract with the U.S. Department of Health and Human Services to supply a stockpile of next-generation safe smallpox vaccines. (BioWorld International)
BioWorld Asia